Published in AIDS Res Hum Retroviruses on March 20, 2002
Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr (2006) 3.93
Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev (2004) 1.48
Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy. PLoS One (2007) 1.47
Defining an evidence-based cutpoint for medication adherence in heart failure. Am Heart J (2008) 1.44
Intensive insulin therapy in the medical ICU. N Engl J Med (2006) 22.37
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics (2005) 5.60
The molecular population genetics of HIV-1 group O. Genetics (2004) 4.53
Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis (2007) 3.80
A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol (2012) 3.72
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood (2009) 3.47
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med (2003) 2.84
U.S. Human immunodeficiency virus type 1 epidemic: date of origin, population history, and characterization of early strains. J Virol (2003) 2.64
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol (2005) 2.35
Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci U S A (2003) 2.31
Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med (2006) 2.22
Critique on the conceptualisation of quality of life: a review and evaluation of different conceptual approaches. Int J Nurs Stud (2006) 2.17
A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res (2009) 2.06
Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (2006) 1.95
A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther (2002) 1.92
First case of Staphylococcus pseudintermedius infection in a human. J Clin Microbiol (2006) 1.83
Prevalence and correlates of nonadherence to antiretroviral therapy in a population of HIV patients using Medication Event Monitoring System. AIDS Patient Care STDS (2004) 1.75
Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (2010) 1.75
Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form. J Virol (2007) 1.74
Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol (2013) 1.69
Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int (2005) 1.65
Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein. J Virol (2005) 1.60
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol (2007) 1.57
Prevalence and consequences of nonadherence to hemodialysis regimens. Am J Crit Care (2007) 1.54
Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDS (2008) 1.54
The spectrum of nonadherence with medication in heart, liver, and lung transplant patients assessed in various ways. Transpl Int (2011) 1.53
A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A (2002) 1.53
Development of a risk assessment tool for deliberate self-extubation in intensive care patients. Intensive Care Med (2004) 1.51
Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs (2003) 1.51
Rationing of nursing care and its relationship to patient outcomes: the Swiss extension of the International Hospital Outcomes Study. Int J Qual Health Care (2008) 1.49
Quantifying differences in the tempo of human immunodeficiency virus type 1 subtype evolution. J Virol (2009) 1.49
Relating increasing hantavirus incidences to the changing climate: the mast connection. Int J Health Geogr (2009) 1.48
Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup a: positively selected sites in the attachment g glycoprotein. J Virol (2004) 1.48
Computerized patient education in kidney transplantation: testing the content validity and usability of the Organ Transplant Information System (OTIS). Patient Educ Couns (2008) 1.42
Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS (2005) 1.41
Pretransplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening. Transplantation (2009) 1.38
Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J Mol Evol (2002) 1.38
The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology (2008) 1.38
HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr (2003) 1.38
Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum (2006) 1.37
Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain. J Virol (2005) 1.36
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One (2010) 1.33
Use of electronic monitoring induces a 40-day intervention effect in HIV patients. J Acquir Immune Defic Syndr (2006) 1.33
Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients. BMC Med Res Methodol (2008) 1.32
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology (2013) 1.30
Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant (2005) 1.28
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr (2006) 1.27
Adherence to the medical regimen during the first two years after lung transplantation. Transplantation (2008) 1.26
Analysis of the serotype and genotype correlation of VP1 and the 5' noncoding region in an epidemiological survey of the human enterovirus B species. J Clin Microbiol (2004) 1.22
Interventions to improve medication-adherence after transplantation: a systematic review. Transpl Int (2009) 1.22
Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antivir Ther (2009) 1.20
Characteristics of hospital inpatient falls across clinical departments. Gerontology (2008) 1.20
Excessive daytime sleepiness is associated with poor medication adherence in adults with heart failure. J Card Fail (2010) 1.19
Falls and consequent injuries in hospitalized patients: effects of an interdisciplinary falls prevention program. BMC Health Serv Res (2006) 1.19
Identification in gelada baboons (Theropithecus gelada) of a distinct simian T-cell lymphotropic virus type 3 with a broad range of Western blot reactivity. J Gen Virol (2004) 1.18
Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001. J Acquir Immune Defic Syndr (2004) 1.17
Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol (2004) 1.17
The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation (2010) 1.16
Limitations to contact tracing and phylogenetic analysis in establishing HIV type 1 transmission networks in Cuba. AIDS Res Hum Retroviruses (2007) 1.16
Mapping sites of positive selection and amino acid diversification in the HIV genome: an alternative approach to vaccine design? Genetics (2004) 1.15
Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther (2008) 1.14
The preanalytical optimization of blood cultures: a review and the clinical importance of benchmarking in 5 Belgian hospitals. Diagn Microbiol Infect Dis (2012) 1.14
Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS (2006) 1.14
Prevalence, patterns and predictors of nursing care left undone in European hospitals: results from the multicountry cross-sectional RN4CAST study. BMJ Qual Saf (2013) 1.13
Different epidemic potentials of the HIV-1B and C subtypes. J Mol Evol (2005) 1.12
Non-adherence to immunosuppressive medication in renal transplant recipients within the scope of the Integrative Model of Behavioral Prediction: a cross-sectional study. Clin Transplant (2009) 1.12
A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J Virol Methods (2005) 1.10
Tenofovir resistance and resensitization. Antimicrob Agents Chemother (2003) 1.10
The association of patient safety climate and nurse-related organizational factors with selected patient outcomes: a cross-sectional survey. Int J Nurs Stud (2012) 1.10
Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon. Infect Genet Evol (2011) 1.10
In vivo characteristics of human immunodeficiency virus type 1 intersubtype recombination: determination of hot spots and correlation with sequence similarity. J Gen Virol (2003) 1.09
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother (2006) 1.08
Predictors of objectively measured medication nonadherence in adults with heart failure. Circ Heart Fail (2012) 1.06
Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation. Curr Opin HIV AIDS (2007) 1.06
Effect of late medication non-compliance on outcome after heart transplantation: a 5-year follow-up. J Heart Lung Transplant (2004) 1.06
Which interventions are used by health care professionals to enhance medication adherence in cardiovascular patients? A survey of current clinical practice. Eur J Cardiovasc Nurs (2010) 1.05
env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors. Antimicrob Agents Chemother (2002) 1.04
Mosaic genomes of the six major primate lentivirus lineages revealed by phylogenetic analyses. J Virol (2003) 1.03
Phylogenetic reconstruction of a known HIV-1 CRF04_cpx transmission network using maximum likelihood and Bayesian methods. J Mol Evol (2004) 1.03
Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. J Gen Virol (2011) 1.03
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J Clin Virol (2007) 1.03
High GUD incidence in the early 20 century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains. PLoS One (2010) 1.03
Complete genome sequence, taxonomic assignment, and comparative analysis of the untranslated regions of the Modoc virus, a flavivirus with no known vector. Virology (2002) 1.02
Phylogeny of primate T lymphotropic virus type 1 (PTLV-1) including various new Asian and African non-human primate strains. Infect Genet Evol (2006) 1.02
Limited cross-border infections in patients newly diagnosed with HIV in Europe. Retrovirology (2013) 1.01